These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28443358)

  • 1. Cerebral rituximab uptake in multiple sclerosis: A
    Hagens MH; Killestein J; Yaqub MM; van Dongen GA; Lammertsma AA; Barkhof F; van Berckel BN
    Mult Scler; 2018 Apr; 24(4):543-545. PubMed ID: 28443358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation Dosimetry Study of [(89)Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography.
    Natarajan A; Gambhir SS
    Mol Imaging Biol; 2015 Aug; 17(4):539-47. PubMed ID: 25500766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.
    Bruijnen S; Tsang-A-Sjoe M; Raterman H; Ramwadhdoebe T; Vugts D; van Dongen G; Huisman M; Hoekstra O; Tak PP; Voskuyl A; van der Laken C
    Arthritis Res Ther; 2016 Nov; 18(1):266. PubMed ID: 27863504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab and multiple sclerosis.
    Kitsos DK; Tsiodras S; Stamboulis E; Voumvourakis KI
    Clin Neuropharmacol; 2012; 35(2):90-6. PubMed ID: 22421587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
    Piccio L; Naismith RT; Trinkaus K; Klein RS; Parks BJ; Lyons JA; Cross AH
    Arch Neurol; 2010 Jun; 67(6):707-14. PubMed ID: 20558389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
    Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
    Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ImmunoPET of Malignant and Normal B Cells with
    Zettlitz KA; Tavaré R; Knowles SM; Steward KK; Timmerman JM; Wu AM
    Clin Cancer Res; 2017 Dec; 23(23):7242-7252. PubMed ID: 28928164
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
    Dunn N; Juto A; Ryner M; Manouchehrinia A; Piccoli L; Fink K; Piehl F; Fogdell-Hahn A
    Mult Scler; 2018 Aug; 24(9):1224-1233. PubMed ID: 28762877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cell depletion in the treatment of multiple sclerosis.
    Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
    Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
    Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
    J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
    Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
    Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple Sclerosis.
    Calabresi PA
    N Engl J Med; 2017 Jan; 376(3):280-282. PubMed ID: 28001486
    [No Abstract]   [Full Text] [Related]  

  • 13. B cell-directed therapies in multiple sclerosis.
    Gasperi C; Stüve O; Hemmer B
    Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cells in multiple sclerosis therapy-A comprehensive review.
    Rahmanzadeh R; Weber MS; Brück W; Navardi S; Sahraian MA
    Acta Neurol Scand; 2018 Jun; 137(6):544-556. PubMed ID: 29512131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging B Cells in a Mouse Model of Multiple Sclerosis Using
    James ML; Hoehne A; Mayer AT; Lechtenberg K; Moreno M; Gowrishankar G; Ilovich O; Natarajan A; Johnson EM; Nguyen J; Quach L; Han M; Buckwalter M; Chandra S; Gambhir SS
    J Nucl Med; 2017 Nov; 58(11):1845-1851. PubMed ID: 28687602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.
    Gasperini C; Haggiag S; Ruggieri S
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1243-53. PubMed ID: 23855792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
    Studer V; Rossi S; Motta C; Buttari F; Centonze D
    J Neuroimmunol; 2014 Nov; 276(1-2):229-31. PubMed ID: 25175066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.
    Cross AH; Stark JL; Lauber J; Ramsbottom MJ; Lyons JA
    J Neuroimmunol; 2006 Nov; 180(1-2):63-70. PubMed ID: 16904756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Zhou H; Han W; Zhang S
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009130. PubMed ID: 22161445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.
    Stüve O; Leussink VI; Fröhlich R; Hemmer B; Hartung HP; Menge T; Kieseier BC
    Arch Neurol; 2009 Feb; 66(2):259-61. PubMed ID: 19204165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.